Adiponectin: Role in Glucose Homeostasis in Relation to BMI in Type 2 Diabetics BC14-BC17
Dr. Satinder Kaur,
Associate Professor, Department of Biochemistry, Dayanand Medical College and Hospital, Civil Lines,
Ludhiana-141001, Punjab, India.
Introduction: Amongst the many adipocytokines discovered in recent times, Adiponectin has drawn much attention for its insulin sensitising, anti-atherogenic and anti-inflammatory actions. Though, Adiponectin is secreted by adipose tissue, its decreased levels are associated with obesity and Type 2 Diabetes Mellitus (T2DM).
Aim: The present investigation was conducted to study the role of Adiponectin in glucose homeostasis in T2DM subjects in relation to Body Mass Index (BMI).
Materials and Methods: Seventy five T2DM patients visiting the Endocrinology OPD of a tertiary care hospital were selected for the study. Patients on thiazolidinediones were not included. They were divided into three groups of 25 each based on BMI. Group A: <25 kg/m2 Group B: 25-29.99 kg/m2 Group C: =30 kg/m2. Waist Hip Ratio (WHR) was recorded. Serum Adiponectin levels were estimated by ELISA, FBS, CRP, HbA1c, insulin and lipid profile was analysed on Cobas 6000 (Roche). Insulin resistance was measured by Homeostasis Model Assessment (HOMA-IR).
Results: A 56% patients had low Adiponectin levels (<10 µg/mL), only 10.8% patients had >25 µg/mL. Group B patients had lowest levels of Adiponectin (11.86±8.79 µg/mL). FBS, HbA1c, insulin levels and HOMA-IR showed a negative correlation with Adiponectin in all the groups but was significant in group B only (r=-0.555, -0.611, -0.477 and -0.528 respectively). CRP and all the fractions of lipid profile (except HDL) showed negative correlation with Adiponectin in all the groups but it was not significant. HDL levels increased with increase in Adiponectin levels in all the groups.
Conclusion: This study reaffirms the significant role that adipose tissue hormones play in pathophysiology of T2DM. Significant negative correlation of glucose, HbA1c, insulin resistance with Adiponectin noted in overweight diabetics supports the hypothesis that these patients can be potential therapeutic target for drugs increasing Adiponectin levels.